The Man Who Faced Ebola First: Dr. Jean-Jacques Muyembe-Tamfum

In 1976, a young Congolese doctor traveled to the village of Yambuku in northern Zaire, now the Democratic Republic of Congo, to investigate a mysterious illness that was killing patients and nurses at a Catholic mission hospital. When he arrived, he later recalled, "the place was deserted. It was as if nobody lived there." His name was Jean-Jacques Muyembe-Tamfum. He took some of the first blood samples from the disease the world would come to know as Ebola, and he has spent the next fifty years fighting it.

A Young Scientist Comes Home

Muyembe trained in medicine in Kinshasa and earned his doctorate in virology at the Catholic University of Leuven in Belgium in the early 1970s, one of a small number of Congolese scientists in the first generation after independence. He came home to teach microbiology at the University of Kinshasa. Before Ebola, he had already worked on cholera and monkeypox in the field, and those outbreaks taught him, he later said, that he "couldn't just study microbes in the laboratory, but needed to get into the field."

The Doctor at Yambuku

The health minister sent Muyembe and a colleague, Dr. Omombo, to Yambuku in September 1976. He had no protective suit. He examined patients, took blood and liver samples by hand and noticed that the wounds where he removed needles would not stop bleeding. "My fingers were covered in blood," he told Scientific American. He washed with soap and water, likely the reason he survived.

Muyembe sent the samples to a laboratory in Antwerp, Belgium. From there they went to the U.S. Centers for Disease Control in Atlanta, where virologists isolated the new virus and named it after the nearby Ebola River. The outbreak killed 280 of the 318 people known to be infected, including most of the hospital's staff.

For decades, Western accounts of the discovery named the European and American scientists who studied the samples abroad. The Congolese doctor who went into the village first and carried the samples out was too often left out of the story, or reduced to a local helper.

His Methods: Survivors, Fieldwork and Science at Home

Muyembe's approach rests on three ideas, and each has reshaped how the world fights epidemics.

The blood of survivors. During the 1995 outbreak in Kikwit, where most people who caught the virus were dying, Muyembe gave eight sick patients transfusions of blood from people who had recovered, reasoning that the survivors' antibodies could fight the virus. Seven of the eight lived. Outside experts said the sample was too small and that the patients might have survived anyway, and the idea was set aside.

It took about twenty years for the world to catch up. Working with Dr. Nancy Sullivan's team at the U.S. National Institutes of Health, Muyembe's institute went back to a Kikwit survivor whose blood still held protective antibodies more than a decade later. From those cells, scientists isolated a single antibody, mAb114. In the PALM trial, run in North Kivu in 2018 and 2019 in the middle of an armed conflict, mAb114 and a second antibody treatment cut deaths sharply, especially among patients treated early. The trial was stopped early in August 2019 because the results were so clear. In December 2020 the U.S. Food and Drug Administration approved mAb114 as Ebanga, one of the first two Ebola treatments ever approved.

The principle of treating patients with survivors' antibodies has since spread far beyond Ebola. Convalescent plasma and lab-made antibody treatments were used around the world during COVID-19.

Going to the patients. Muyembe insisted that outbreak science be done where the sick are. His teams brought mobile laboratories close to outbreaks so that samples could be tested in hours instead of weeks, worked with local leaders and families, and treated safe, dignified burial as part of medicine rather than an afterthought.

Science at home. He argued that Congolese samples should be studied by Congolese scientists in Congo, not shipped abroad by default.

The Laboratory He Built

As director-general of Congo's National Institute for Biomedical Research (INRB) in Kinshasa, Muyembe turned a poorly equipped institute into a leading center for outbreak research. Today INRB sequences virus genomes, runs clinical trials and trains a new generation of African virologists, and it was at the center of the response to the 2018–2020 outbreak and to Congo's later outbreaks of Ebola and mpox.

He has been honored with the Royal Society Africa Prize, a place on Nature's list of ten people who mattered in science in 2018, and the Hideyo Noguchi Africa Prize in 2019.

Why It Matters

Muyembe's career is a reply to the old story that Africa is only a place where diseases happen and outsiders bring the cures. The treatment that turned Ebola from a near-certain death sentence into a survivable disease began with a Congolese doctor, Congolese survivors and a Congolese laboratory. In eastern Congo today, the people tracing contacts and running isolation wards stand on the work of a doctor who walked into Yambuku in 1976 and refused to leave the fight.

---